ArticleAutoimmunity2010
ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset.
Article in Autoimmunity, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03352674 (Open Label Randomized Multicenter Clinical Trial to Compare Immunogenicity of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients), which is not on this map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Open Label Randomized Multicenter Clinical Trial to Compare Immunogenicity of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Pooled it
- Zinc transporter 8 (ZnT8) autoantibody epitope specificity and affinity examined with recombinant ZnT8 variant proteins in specific ZnT8R and ZnT8W autoantibody-positive type 1 diabetes patients.Clinical and experimental immunology · 2015Trial
- Prevalence and Phenotypic Correlations of GAD65 and ZnT8 Autoantibodies in Young-Onset Diabetes: A Pilot Study in a Tertiary Centre in Bangladesh.Endocrinology, diabetes & metabolism · 2026Article
- Continuously High Titers of Multiple Islet-associated Autoantibodies in an Individual with an Elderly Onset of Type 1 Diabetes Mellitus and Basedow's Disease: A Case Report with a Review of Literature.Internal medicine (Tokyo, Japan) · 2026Review
- A case of type 1 diabetes mellitus with a single-positive zinc transporter 8 antibody who developed diabetic ketoacidosis during chemotherapy for colorectal cancer.Diabetology international · 2025Article
- A case of latent autoimmune diabetes in the young positive for zinc transporter 8 antibody with type 2 diabetes characteristics.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2025Article
- Measuring anti-islet autoimmunity in mouse and human by profiling peripheral blood antigen-specific CD4 T cells.Science translational medicine · 2023Article
- Zinc transporter 8 autoantibody testing requires age-related cut-offs.BMJ open diabetes research & care · 2021Article
- Zinc transporter 8 (ZnT8) autoantibody prevalence in black South African participants with type 1 diabetes.BMC endocrine disorders · 2021Article
- Zinc.Advances in food and nutrition research · 2021Review
- Islet, thyroid and transglutaminase antibodies in adult Bulgarian patients with type 1 diabetes.Endocrine · 2020Article
- Zinc transporter 8 autoantibody in the diagnosis of type 1 diabetes in children.Clinical and experimental pediatrics · 2020Article
- Zinc transporter 8 autoantibodies complement glutamic acid decarboxylase and insulinoma-associated antigen-2 autoantibodies in the identification and characterization of Japanese type 1 diabetes.Journal of diabetes investigation · 2020Article
- Serum C-peptide and osteocalcin levels in children with recently diagnosed diabetes.Endocrinology, diabetes & metabolism · 2020Article
- Type 1 diabetes genetic risk score discriminates between monogenic and Type 1 diabetes in children diagnosed at the age of <5 years in the Iranian population.Diabetic medicine : a journal of the British Diabetic Association · 2019Article
- Influence of Disease Duration on Circulating Levels of miRNAs in Children and Adolescents with New Onset Type 1 Diabetes.Non-coding RNA · 2018Article
- Prevalence of ZnT8 Antibody in Turkish Children and Adolescents with New Onset Type 1 DiabetesJournal of clinical research in pediatric endocrinology · 2018Article
- Osteoprotegerin autoantibodies do not predict low bone mineral density in middle-aged women.Bone reports · 2017Article
- Zinc as a Gatekeeper of Immune Function.Nutrients · 2017Review
- Prokaryotic expression and characterization of the heterodimeric construction of ZnT8 and its application for autoantibodies detection in diabetes mellitus.Microbial cell factories · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
Autoantibodies to the islet-specific zinc transporter isoform 8 (ZnT8) are detected in the majority of type 1 diabetes patients prior to and at clinical diagnosis. The presence of ZnT8Ab after diagnosis has not been investigated. This study analyzed the autoantibody response to ZnT8 in regard to age at onset and disease duration. Two new onset type 1 diabetes patient cohorts with different age distributions at onset (2-17 and 15-34 years of age at onset), a longitudinal subset of the younger type 1 diabetes patient cohort (n = 32), and a cohort of GAD65Ab-positive LADA patients (n = 47) was analyzed for the presence of autoantibodies directed to the two major isoforms, ZnT8-Arginine (ZnT8R) and ZnT8-Tryptophan (ZnT8W). The majority of type 1 diabetes patients tested positive for ZnT8Ab to both isoforms. ZnT8Ab titers were significantly higher in the younger type 1 diabetes patients as compared with the older cohort (ZnT8RAb at a median of 148 and 29 U/ml, respectively, p < 0.001) (ZnT8WAb at a median of 145 and 58 U/ml, respectively, p < 0.01). ZnT8RAb and ZnT8WAb titers were significantly lower in the LADA patients (ZnT8RAb at a median of 14 U/ml, ZnT8WAb at a median of 25 U/ml) as compared with either type 1 diabetes cohorts. In our longitudinal analysis of type 1 diabetes patients after clinical diagnosis, ZnT8Ab levels to both isoforms declined significantly during the initial year of disease (ZnT8RAb from a median of 320-162 U/ml, p = 0.0001; ZnT8WAb from a median of 128-46 U/ml, p = 0.0011). The antibody titers further declined during the following 4 years (p < 0.0001). We conclude that ZnT8Ab presents a useful marker for type 1 diabetes, especially in younger patients at disease diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.